Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,612.00
Bid: 1,613.00
Ask: 1,614.00
Change: 12.00 (0.75%)
Spread: 1.00 (0.062%)
Open: 1,608.00
High: 1,619.00
Low: 1,604.50
Prev. Close: 1,600.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

Wed, 01st May 2024 11:55

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

The FTSE 100 index slipped just 1.15 points to 8,142.98. The FTSE 250 was down 35.58 points, 0.2%, at 19,929.81, and the AIM All-Share was up 3.07 points, 0.4%, at 763.81.

The Cboe UK 100 was flat at 813.38, the Cboe UK 250 fell 0.2% to 17,252.36, and the Cboe Small Companies was up 0.1% at 15,743.17.

Financial markets in Paris and Frankfurt are closed on Wednesday.

The Fed announces its latest interest rate decision at 1900 BST. A press conference with Chair Jerome Powell follows half an hour later.

Scope Markets analyst Joshua Mahony commented: "Today sees the Federal Reserve step up to the plate once again, with Jerome Powell holding the markets in his hands. Recent concerns around a resurgence in inflation pressures have pushed back the expected rate cuts that had until recently been scheduled to commence next month. The market pricing for a June rate cut has shifted from 56% to just 6% in the past month, but even more incredibly we have seen it pushed all the way back to December, bypassing three meetings in the process.

"With the Fed's March dot plot having laid out plans to cut three times this year, it is evident that the recent inflationary surge has similarly taken Powell and his colleagues off-guard. Today is the opportunity for him to set new expectations, and there is understandable concern that this meeting will be dominated by a more hawkish tone. Given the dramatic shift in expectations by the markets, bulls will hope that Powell could provide a glimmer of hope that things may not be as bad as markets are portraying."

While the Fed is not slated to release another summary of economic projections, the press conference following the decision offers a chance for Chair Powell to offer some thoughts on the US interest rate outlook.

With a rate cut hat-trick for 2024 now a distant prospect, the dollar has been supported.

The pound was quoted at USD1.2485 early Wednesday, down from USD1.2523 at the time of the London equities close on Tuesday. The euro stood at USD1.0660, down from USD1.0690. Against the yen, the dollar was trading at JPY157.95, up from JPY157.44.

Pepperstone analyst Michael Brown said the "tide" could turn on the dollar soon, however.

"Although the USD has gained ground against all G10 peers since the turn of the year, signs are starting to emerge that the tide may well be turning against the greenback, as Fed pricing reaches 'max hawk', growth appears to soften, and geopolitical risk seems to dissipate," Brown added.

Still to come on Wednesday is the latest US ADP jobs report at 1315 BST.

Equities in New York are called to open lower. The Dow Jones Industrial Average is called down 0.3%, the S&P 500 down 0.5% and the Nasdaq Composite 0.8% lower.

In London, Smith & Nephew shares rose 2.7%, the best large-cap performer. The medical devices maker said first-quarter revenue rose 2.2% on a reported basis to USD1.39 billion from USD1.36 billion.

"Revenue growth in the first quarter was driven by solid performance in our Orthopaedics and Sports Medicine & ENT businesses, partially offset by some anticipated softness in Advanced Wound Management," Chief Executive Officer Deepak Nath said.

"We are confident in our outlook and look forward to all three of our business units contributing as we deliver another year of strong revenue growth."

Smith & Nephew maintained annual guidance, expecting reporting revenue growth of 4.3% to 5.3%.

GSK added 1.9% as it raised annual guidance. Shingles drug, Shingrix, was one stand-out performer in its first-quarter, but the drugmaker reported momentum across all business areas.

The London-based pharmaceutical maker said revenue in the first-quarter of the year was up 5.9% to GBP7.36 billion from GBP6.95 billion a year prior.

Pretax profit, however, weakened 29% to GBP1.36 billion from GBP1.91 billion. GSK reported 'other' expenses worth GBP533 million, swinging from GBP297 million in gains a year prior and hurting its bottom line. Cost of sales rose 1.5% to GBP1.97 billion from GBP1.94 billion.

GSK now expects annual revenue to rise at the upper part of its 5% to 7% range, at constant currency.

It expects constant currency operating profit growth in its core operations of 9% to 11%, its outlook raised from 7% to 10%. Core earnings per share growth of 8% to 10% at constant currency is now expected, the guidance bumped up from 6% to 9%.

Aston Martin shares went into reverse, losing 5.2%, sitting at the rear of the FTSE 250. The Gaydon, England-based carmaker said revenue in the first-quarter fell 10% to GBP267.7 million from GBP295.9 million a year earlier. Its pretax loss widened 87% to GBP138.8 million from GBP74.2 million.

The company reported 945 vehicle sales, down 26% from 1,269.

AJ Bell analyst Russ Mould commented: "Luxury car manufacturer Aston Martin has been sent to the stock market equivalent of the scrapyard after struggling to kick into gear. The company has reported a doubling of losses in the first quarter and missed expectations across the board – including on volumes. Aston Martin has stopped production on some of its core models ahead of the launch of a new range of vehicles which the company expects to power growth in the second half of this year and beyond, but there is little reason for investors to place any faith in this strategy.

"The company's valuation is a fraction of what it was when it listed back in 2018, rendering initial comparisons with Ferrari as ridiculous as setting a park jogger up against an Olympic middle-distance runner. Despite a recent refinancing, Aston Martin is still burdened with a hefty debt pile and it's likely in the last chance saloon at this point. If the new launches don't go well it's hard to see what road the business can take next."

On AIM, there was some M&A impetus for Trinity Exploration and Alpha Financial Markets Consulting shares.

Alpha Financial Markets Consulting rose 39% after it confirmed private equity interest. It has a market capitalisation of GBP531.5 million.

It said it has received a non-binding indicative proposal from Bridgepoint Advisers, and added that Cinven is also mulling an offer. The duo have until the close of play on May 29 to confirm whether they plan to make an offer for the specialist consultancy services provider.

Trinity Exploration surged 43%, while Touchstone Exploration fell 3.9%. Touchstone said it has struck an all-share deal to acquire Trinity.

The all-share agreement values the latter at GBP24.1 million. Touchstone Exploration, an oil and natural gas exploration and production active in Trinidad & Tobago, said the deal will create a "leading Trinidadian operator of scale".

It said: "The addition of Trinity's existing production portfolio, along with its exploration and development assets, will position the combined group as one of the leading independent operating companies dedicated to investing in both onshore and offshore activity to grow Trinidadian oil and gas production."

As part of the deal, Trinity shareholders will receive 1.5 new Touchstone shares for each Trinity share owned. Trinity shareholders will own just under 20% of the combined firm. Trinity directors consider the terms of the deal to be "fair and reasonable".

Brent oil was quoted at USD85.23 a barrel early on Wednesday afternoon London time, down from USD86.42 late Tuesday. Gold was quoted at USD2,291.09 an ounce, down from USD2,298.10.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.